# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Within the last quarter, Forma Therapeutics Hldgs (NASDAQ:FMTX) has observed the following analyst ratings:
Keybanc cut the price target for Broadcom Inc. (NASDAQ: AVGO) from $780 to $700. Broadcom shares rose 2.3% to $503.14 in pr...
Credit Suisse analyst Tiago Fauth downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Neutral and announces...
HC Wainwright & Co. analyst Robert Burns downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Neutral and lower...
Gainers
Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.
Jefferies analyst Maury Raycroft downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Hold and lowers the price tar...